Company Overview
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Why Investors Should Care
Revenue has grown at a 175.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.17.
Recent Developments
- Dec 2025 Revenue of $109.16M (+1556.8% YoY); net profit $-9.58M.
- Trailing 12 Months Year-on-year growth — revenue +1556.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 175.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 175.88% |
| 1 Year: | 1,556.76% |
Stock Price Performance
| 1 Year: | +288.37% |
| 6 Months: | -29.59% |
| 3 Months: | -2.36% |
| 1 Month: | +3.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)49.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 175.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 29.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IPSC Century Therapeutics, Inc. PHARMA | 2.07 | -2.23 | $374.83M | 0.00% | -8.49% | -49.65% | 175.88% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 1.06M | 1.40M | 2.22M | 1.72M | 99.00K | 148.00K | 855.00K | 771.00K | 791.00K | 109.16M | - | - | - |
| Operating Income | - | -15.52M | -13.13M | -18.06M | -23.02M | -25.83M | -37.44M | -31.35M | -31.74M | -32.08M | -35.08M | -35.63M | -31.31M | -34.76M | -34.79M | 74.18M | -34.66M | -36.12M | -23.68M |
| Net Income | -9.67M | -15.30M | -13.07M | -18.35M | -23.27M | -26.01M | -37.51M | -30.99M | -30.75M | -31.26M | -33.29M | -32.72M | -28.06M | -31.21M | -31.23M | 76.56M | -32.54M | -34.42M | -21.64M |
| Diluted EPS | - | - | -1.75 | -2.39 | -1.93 | -0.48 | -0.66 | -0.54 | -0.53 | -0.53 | -0.56 | -0.55 | -0.45 | -0.38 | -0.37 | 0.89 | -0.38 | -0.40 | -0.11 |
| R&D Expense | - | 8.48M | 10.81M | - | 18.93M | 19.55M | - | - | - | - | - | - | - | - | - | - | - | 12.00K | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 5.20M | 2.23M | 6.59M | 109.16M |
| Operating Income | -53.90M | -94.88M | -133.83M | -146.55M | -138.14M | -17.27M |
| Net Income | -53.58M | -95.82M | -130.93M | -136.67M | -126.57M | -9.58M |
| Diluted EPS | -7.16 | -2.96 | -2.96 | -2.30 | -1.61 | -0.14 |
| R&D Expense | 39.68M | 75.65M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 106.78M | - | 486.54M | 360.69M | 353.22M | 223.70M |
| Current Assets | - | - | - | 319.72M | 176.99M | 194.05M | 120.77M |
| Cash & Equivalents | - | 27.21M | - | 84.27M | 47.32M | 58.44M | 61.85M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | 780.00K | 2.23M | 1.52M | 667.00K |
| Total Liabilities | - | 33.43M | - | 183.81M | 175.94M | 191.85M | 64.77M |
| Current Liabilities | - | 12.11M | - | 29.82M | 17.85M | 129.78M | 20.23M |
| Long Term Debt | - | 9.64M | 8.90M | 3.74M | - | - | - |
| Total Debt | - | - | - | 49.41M | 48.17M | 53.83M | 43.56M |
| Total Equity | -91.86M | -106.41M | - | 302.74M | 184.75M | 161.36M | 158.94M |
| Shares Outstanding | - | - | - | 58.47M | 60.34M | 85.84M | 87.52M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -41.27M | -89.00M | 14.05M | -88.35M | -110.14M | -103.88M |
| Investing Cash Flow | -22.76M | -298.34M | -13.13M | 61.13M | 47.48M | 107.50M |
| Financing Cash Flow | 47.69M | 417.77M | 27.16M | -9.72M | 74.56M | 173.00K |
| Capital Expenditure | -9.82M | -44.97M | -30.60M | -13.74M | -154.00K | -848.00K |
| Free Cash Flow | -51.09M | -133.97M | -16.55M | -102.08M | -110.29M | -104.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | -2,574.2% | -6,556.9% | -2,096.5% | -15.8% |
| Net Margin % | - | - | -2,518.4% | -6,115.1% | -1,920.9% | -8.8% |
| ROE % | 50.3% | - | -43.2% | -74.0% | -78.4% | -6.0% |
| ROCE % | -56.9% | - | -29.3% | -42.7% | -61.8% | -8.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 9.80% | 17.75M | $33.02M |
| 2 | TCG Crossover Management, LLC | 9.80% | 17.75M | $33.02M |
| 3 | Versant Venture Management, LLC | 6.72% | 12.17M | $22.63M |
| 4 | Deep Track Capital, Lp | 5.23% | 9.46M | $17.60M |
| 5 | Commodore Capital Lp | 4.80% | 8.70M | $16.17M |
| 6 | RTW Investments LP | 4.80% | 8.70M | $16.17M |
| 7 | Venrock Adviser, LLC | 4.80% | 8.70M | $16.17M |
| 8 | Blackrock Inc. | 4.47% | 8.09M | $15.05M |
| 9 | Vanguard Capital Management LLC | 3.15% | 5.70M | $10.61M |
| 10 | Balyasny Asset Management LP | 3.05% | 5.52M | $10.27M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IPSC
Century Therapeutics (NASDAQ: IPSC) officer plans stock sale partly to cover taxes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOX0ZGSTltOF9oUzNtZjJVaDB1Q1FYODZHaV81RWRDMktIcVJsdHktLV9yOVl2VTV5aGx0NWtnLWx1ZktiLVpkMEdMU25DWkM2TGhRY0Jfc1NjN2l4UVVWcGl5cmlPcTBWajBXeHpGOFJfaS1yeVE2MGZMSGZrMENyajZTZHpTeG45ZERJYV…
IPSC - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5CX24zcl8zLU95NUs3Tm1iaW5kMnlmVHphTXU2OEZzN3pUNnJ0U18wX0JzWEpTUnZyUEJsM29zRzItS3FOZEE?oc=5" target="_blank">IPSC</a> <font color="#6f6f6f">Finviz</font>…
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxOQS1ydlB6ZHRPTmRNbHl4Z0RxM25TaEN5QlVGMXRTQWJKbEZZMDZSOTJva3haRXFiTzhXeVM5RmtSQ1NUdm1UTzFUQUhOWnd3bHQ1Y1BVUENrVE9YdFRQbkJVQ3pLNEpWVl9pQjJHeUY3NlVrZTF3cy1POHZXSWZmaUlUM3U0ZVNtanJXYU…
$IPSC stock is up 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQblRaRjJnd09QeE4zZHV3QTlZa2dKMFh3T1lRSEdlTWVZRVdtRTRJOXk0Q2ppT0piSXJ2V2kyTFVUTU5SdmNzU09nREtPZXgxeXdnYjR2NlFlTndKSlBBZGVBYi10WTdfRWhQcTVsNVY5dWRnRHFPZmZwWEw5NHIydmpjbEZyZmdVYUJkTH…
Century Therapeutics: A Biotech With Interesting Optionality Opportunities (NASDAQ:IPSC) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPTFkxaDNwMzhURWNXclRLVDFWRzJhV2lCRWZWMWNTWjVfNVVzUS1RWE9GLXBtelZQUmlmZDRZd2szQllMMTd1RVB2eW9WXy1GTkNTWVljT254QkRlWjdhbXRfRkhaV1ZVQTAwcDZzaTYtNkxFUFd4bXZzMGxNbEdwcS1ZeXRfeF9QVFBheG…
Will Century Therapeutics (NASDAQ:IPSC) Spend Its Cash Wisely? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOdXdvNkswbWRPVnFKR0FkLUtCMHVvVGtpUlJzb1Y4ci1ySTg5S0NuVlQ3VFpkdUgwVEppM3ZmQm9Vc1F3R1dPZHFSYjlpckNDYzctcFJGYndMLWR2OGFZOFRIUGc1U0VUQ1lpc0phY3ZkOEdiTW5JQm1Gd2t3TTRpczM4bmRmcXlacHlRdl…
IPSC — Frequently Asked Questions
What is the current share price of Century Therapeutics, Inc. (IPSC)?
As of 2026-09-19 21:16 PDT, Century Therapeutics, Inc. (IPSC) trades at $2.07 on NasdaqCM. Its 52-week range is $0.46 to $2.94.
What is the market capitalisation of IPSC?
Century Therapeutics, Inc. (IPSC) has a market capitalisation of $374.83M on NasdaqCM.
What is the P/E ratio of IPSC?
IPSC trades at a trailing price-to-earnings (P/E) ratio of -2.23. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.45.
What is the return on equity (ROE) of IPSC?
IPSC has a return on equity (ROE) of -49.65%. Its return on capital employed (ROCE) is -8.49%.
Is IPSC a good stock to buy?
This page provides a data-driven analysis of Century Therapeutics, Inc. (IPSC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.